Paccal Vet is being evaluated in a dose-determination clinical study in cats with cancer (solid tumors). The study initially involves two clinics in Washington and Oregon, with potential expansion. The study is led by CASTR Alliance, the same contract research organization (CRO) conducting Vivesto’s pilot study in dogs. The U.S. FDA’s Center for Veterinary Medicine (CVM) has confirmed that the cat study may proceed under the approved INAD (Investigational New Animal Drug).
Read more about the study here and apply to participate in the study here.